A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Phase 2 Unknown 30 enrolled Second Affiliated Hospital of Soochow University

NaSingle-groupOpen-labelTreatment

Summary

Exploring the efficacy and safety of recombinant human vascular endothelial inhibitor (Endo) in combination with Bragg therapy in advanced refractory non-small cell lung

Timeline

Start: 2023-06-16
Primary completion: 2024-12-30
Completion: 2024-12-31

Publications

Huang S, Yang X, Zhao X, Kong Y, Zhang L, Xing P. Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol). Transl Lung Cancer Res. 2026 May 31;15(5):153. doi: 10.21037/tlcr-2026-1-0203. Epub 2026 May 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Endostar	Protein / enzyme biologic	210 mg	Intravenous
Background	aldesleukin	Protein / enzyme biologic	2e+06 iu	Subcutaneous
Background	sargramostim	Protein / enzyme biologic	200 ug	Subcutaneous

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications